Instituto Universitario de Investigación en Neuroquímica
Centro/Instituto
![Foto de Instituto Universitario de Investigación en Neuroquímica](/img/uploaded/210288F0EBF11B5B400384EE1F7A6332.jpg)
![Foto de Fundación Hospital Alcorcón](/img/noimage_org.png)
Fundación Hospital Alcorcón
Alcorcón, EspañaPublicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (30)
2018
2016
-
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400
2015
-
Endocannabinoids and Neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others
Handbook of Experimental Pharmacology (Springer New York LLC), pp. 233-259
2014
-
A restricted population of CB1 cannabinoid receptors with neuroprotective activity
Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262
-
Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias
British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489
2013
-
Feasibility and safety of hospital discharge 24 hours after laparoscopic radical prostatectomy
Archivos Espanoles de Urologia, Vol. 66, Núm. 10, pp. 931-938
-
Resultados oncológicos en pacientes potencialmente candidatos a vigilancia activa sometidos a prostatectomía radical
Actas Urologicas Espanolas, Vol. 37, Núm. 10, pp. 603-607
-
Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour
BJU International, Vol. 111, Núm. 4 B
2011
-
GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up
European Urology, Vol. 60, Núm. 4, pp. 734-739
-
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease
Brain, Vol. 134, Núm. 1, pp. 119-136
-
Prospects for cannabinoid therapies in basal ganglia disorders
British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378
2010
-
The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors
Neurobiology of Disease, Vol. 37, Núm. 2, pp. 434-440
2009
-
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
GLIA, Vol. 57, Núm. 11, pp. 1154-1167
-
Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study
Psychiatric Genetics, Vol. 19, Núm. 6, pp. 336
-
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Brain, Vol. 132, Núm. 11, pp. 3152-3164
-
The endocannabinoid system in neuropathological states
International Review of Psychiatry, Vol. 21, Núm. 2 SPEC. ISS., pp. 172-180
2008
-
Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa
Journal of Histochemistry and Cytochemistry, Vol. 56, Núm. 5, pp. 511-516
-
Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance
Neuroscience, Vol. 153, Núm. 3, pp. 687-699
-
The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis
Journal of Biological Chemistry, Vol. 283, Núm. 19, pp. 13320-13324
2007
-
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45